Alicaforsen: Phase II; Phase III for Crohn's disease

ISIS began a 6-week U.S. and European double-blind, placebo-controlled Phase II trial of an enema formulation of alicaforsen (ISIS 2302) in about 100 patients. The compound also is in a Phase II trial...